Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Start Date
4/1/2016
Completion Date
10/1/2040
Summary
The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having "borderline resectable" disease treated with preoperative chemo-radiotherapy fair somewhat better - although many of these patients are not converted to resectability. It may be argued that intensification of local and regional therapy might 1.) Increase the share of patients able to undergo curative surgery and 2.) Improve the local disease control interval and extend survival for patients who remain unresectable. Therefore, the purpose of this research study is to determine if an increase in the number of surgical resection pancreatic adenocarcinoma is higher than historical data by using a combined treatment of proton radiation with capecitabine (oral chemotherapy).
Detailed Description
Participants as part of this research study will receive Proton radiation over 6 weeks with oral chemotherapy (capecitabine) only taken on radiation days. In addition, If surgery is an option, then surgical resection will be performed at least 8 weeks after treatment with radiation and chemotherapy.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Proton Radiation
Capecitabine
Surgical resection
Conditions
Locations
University of Florida Proton Therapy Institute
Jacksonville, Florida 32206
United States
Northwestern Medicine Chicago Proton Center
Warrenville, Illinois 60555
United States
McLaren Proton Therapy Center
Flint, Michigan 48532
United States
Inova Schar Cancer Institute
Fairfax, Virginia 22031
United States